FRANCE - EdRIP closes EUR 150m fund
Edmond de Rothschild Investment Partners (EdRIP) has closed its new venture fund, BioDiscovery 3, on EUR 150m.
The fund will invest up to EUR 15m in 15 to 20 European life science companies across all stages of development. Investments will cover both therapeutic drug development companies and a combination of medical technology and molecular diagnostic companies.
Investors in the fund include La Compagnie Financiere Edmond de Rothchild, La Caisse des Dépots and Amgen. The fund takes over from BioDiversity 2 which closed in 2005 on EUR 80m.
More on Venture
Redalpine expands leadership team amid CHF 1bn-plus fundraise
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds
Iron Wolf Capital targets EUR 70m for second vehicle
Baltic investor anticipates early 2024 launch and will focus on early-stage AI and deeptech startups
Siena aims to hold new VC secondaries fund first close in late 2023 or early 2024
Secondary investments specialist will target EUR 30m to EUR 50m for new fund
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater